Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation

Nov 5, 2026
Isomorphic Labs is discussing a $5 billion funding round at a $50 billion valuation as it prepares to begin its first clinical trials.

Isomorphic Labs is in talks to raise $5 billion at a $50 billion valuation, according to Tech Funding News, citing Bloomberg. The report says founder Demis Hassabis expects the AI drug design company to begin its first clinical trials by the end of December. The financing is not final, and its terms could change.

The DeepMind spinout raised $600 million in March 2025 and closed a $2.1 billion Series B round in May, led by Thrive Capital. A completed $5 billion round would bring its external funding to about $7.7 billion.

Isomorphic Labs uses a collection of AI models called the Isomorphic Drug Design Engine to predict molecular structures and interactions. It has internal drug programs in oncology and immune disorders, along with partnerships with Eli Lilly, Novartis, and Johnson & Johnson.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

Guide
10 most valuable public AI chip companies

10 most valuable public AI chip companies

Publicly traded companies designing merchant silicon for AI computing, ranked by market capitalization at the close of 23 October 2026.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.